Strata Critical Medical, Inc. (SRTA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Strata Critical Medical, Inc. (SRTA) Industrial Operations Profile

Strata Critical Medical, Inc. specializes in time-critical logistics for the healthcare sector, providing air and ground transportation of human organs for transplant across the United States. With a focus on specialized medical services, the company operates within the Airlines, Airports & Air Services industry, serving healthcare providers nationwide.

What Is the Investment Thesis for SRTA?

Strata Critical Medical, Inc. presents a focused investment opportunity within the specialized medical logistics sector. With a P/E ratio of 10.27 and a profit margin of 22.4%, the company demonstrates strong profitability. Key value drivers include the increasing demand for organ transplants and the critical need for timely and reliable transportation services. Growth catalysts include potential expansion into new geographic markets and partnerships with additional healthcare providers. The company's future performance will depend on its ability to maintain its market position and capitalize on growth opportunities within the healthcare logistics industry.

Based on FMP financials and quantitative analysis

SRTA Key Highlights

Market Cap of $444M reflects the company's current valuation in the market.

• P/E Ratio of 10.27 indicates the company's earnings relative to its stock price.
• Profit Margin of 22.4% demonstrates the company's efficiency in generating profit from its revenue.
• Gross Margin of 20.6% shows the company's profitability after deducting the cost of goods sold.
• Beta of 2.11 suggests the stock is more volatile than the overall market.

Who Are SRTA's Competitors?

SRTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SRTA's Key Strengths?

Specialized expertise in organ transportation.

• Established relationships with healthcare providers.
• Efficient logistics network.
• Strong reputation for reliability.

What Are SRTA's Weaknesses?

High dependence on organ transplant volumes.

• Limited geographic diversification.
• Vulnerability to economic downturns.
• High beta indicates significant market volatility.

What Could Drive SRTA Stock Higher?

Expansion of partnerships with transplant centers and organ procurement organizations to increase service volume.

• Investment in advanced tracking and monitoring technologies to improve logistics efficiency.
• Potential acquisitions of smaller medical logistics companies to expand geographic reach within the next year.
• Securing government contracts for medical transportation services to stabilize revenue streams.

What Are the Key Risks for SRTA?

Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $25.5M recently.
• Economic downturns could reduce the volume of organ transplants, impacting revenue.
• Increased competition from larger logistics companies entering the medical transportation market.
• Changes in healthcare regulations could affect the demand for organ transportation services.
• Disruptions to transportation networks due to weather or other unforeseen events.
• High beta indicates significant market volatility, potentially affecting investor confidence.

What Are the Growth Opportunities for SRTA?

• Expansion into New Geographic Markets: Strata Critical Medical, Inc. has the opportunity to expand its services into underserved geographic areas within the United States. By establishing partnerships with healthcare providers in these regions, the company can increase its market share and revenue. The market size for medical logistics in underserved areas is estimated to be substantial, with potential for significant growth in the coming years. Timeline: Within the next 2-3 years.
• Partnerships with Healthcare Providers: Forming strategic alliances with hospitals, transplant centers, and organ procurement organizations can provide Strata Critical Medical, Inc. with a steady stream of business. These partnerships can ensure that the company is the preferred provider for organ transportation services. The market for healthcare partnerships is competitive, but Strata Critical Medical, Inc.'s specialized expertise gives it a competitive advantage. Timeline: Ongoing.
• Technological Advancements in Logistics: Investing in advanced tracking and monitoring technologies can improve the efficiency and reliability of Strata Critical Medical, Inc.'s services. Real-time tracking of organs and enhanced communication systems can reduce the risk of delays and improve patient outcomes. The market for logistics technology is rapidly evolving, with new innovations emerging regularly. Timeline: Ongoing.
• Diversification of Medical Services: Expanding beyond organ transportation to include other time-critical medical services, such as the transport of blood products and medical equipment, can diversify Strata Critical Medical, Inc.'s revenue streams. This diversification can reduce the company's reliance on organ transplants and provide additional growth opportunities. The market for diversified medical logistics services is substantial and growing. Timeline: Within the next 3-5 years.
• Government Contracts and Funding: Securing government contracts and funding for medical logistics services can provide Strata Critical Medical, Inc. with a stable source of revenue. Government agencies often require specialized transportation services for medical supplies and equipment, creating opportunities for the company. The market for government contracts is competitive, but Strata Critical Medical, Inc.'s expertise in organ transportation can give it a competitive edge. Timeline: Ongoing.

What Are SRTA's Competitive Advantages?

• Specialized expertise in time-critical medical logistics.
• Established relationships with hospitals and organ procurement organizations.
• Dedicated fleet of aircraft and ground vehicles for organ transportation.
• Reputation for reliability and efficiency in the medical community.

What Does SRTA Do?

Founded in 2014 and headquartered in New York, Strata Critical Medical, Inc. has evolved into a key player in the time-critical logistics sector for healthcare. Originally known as Blade Air Mobility, Inc., the company rebranded in August 2025 to better reflect its core focus on medical logistics. Strata Critical Medical provides specialized air and ground transportation services, primarily focused on the movement of human organs for transplant. These services are essential for healthcare providers needing rapid and reliable transport solutions. The company's operations span across the United States, ensuring that organs reach their destination within the crucial timeframes required for successful transplants. Strata Critical Medical operates with a fleet of specialized aircraft and ground vehicles, equipped to handle the sensitive nature of medical cargo. With a workforce of 310 employees, Strata Critical Medical is dedicated to providing efficient and secure logistics solutions to the healthcare industry.

What Products and Services Does SRTA Offer?

• Provides air transportation of human organs for transplant.
• Offers ground transportation of human organs for transplant.
• Delivers time-critical logistics solutions to healthcare providers.
• Specializes in medical services related to organ transplantation.
• Operates across the United States.
• Ensures secure and efficient transport of medical cargo.
• Coordinates logistics for organ procurement organizations and transplant centers.

How Does SRTA Make Money?

• Generates revenue through transportation fees for organ delivery.
• Contracts with hospitals and organ procurement organizations for logistics services.
• Utilizes a network of aircraft and ground vehicles for transportation.
• Provides specialized medical services to support organ transplantation.

What Industry Does SRTA Operate In?

Strata Critical Medical, Inc. operates within the Airlines, Airports & Air Services industry, specifically focusing on the niche market of medical logistics. The industry is driven by the increasing demand for organ transplants and the critical need for rapid transportation. The competitive landscape includes specialized logistics providers and traditional transportation companies. Strata Critical Medical differentiates itself through its focus on time-critical medical transport and specialized services. The global healthcare logistics market is expected to grow, driven by technological advancements and increasing healthcare expenditure.

Who Are SRTA's Key Customers?

• Hospitals requiring organ transplant services.
• Organ procurement organizations needing transport solutions.
• Transplant centers coordinating organ transplantation.
• Healthcare providers needing time-critical logistics.

Company Profile

Strata Critical Medical, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Melissa Tomkiel. SRTA has traded publicly since 2019.

Return on equity for Strata Critical Medical, Inc. stands at 14.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.1%, showing how much profit it generates from its asset base. SRTA trades at a trailing price-to-earnings ratio of 10.27, below the Industrials sector average of ~28.00x. Its free cash flow yield is -9.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.64 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.9%, the inverse of the P/E and a quick read on earnings relative to price.

SRTA Valuation & Market Position

With a $444M market cap, Strata Critical Medical, Inc. sits in the small-cap segment of the market. Analyst price targets span from $7.25 to $7.25, with a consensus of $7.25. At the current price of $5.13, that implies approximately 41% upside potential. Relative to its peer group, SRTA's quantitative score of 63/100 is above the peer average of 42/100.

Quarterly Financial Performance: Strata Critical Medical, Inc.

Revenue for Strata Critical Medical, Inc. came in at $72.5M during Q2 FY2026, a 7.6% improvement versus the preceding quarter. The company recorded a net loss of $10.5M, with diluted EPS of $-0.12. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Industrials company. Across the four most recent quarters, SRTA averaged $0.12 in diluted EPS.

Strata Critical Medical, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 5.13 places it in the safe zone, indicating low near-term bankruptcy risk.

Strata Critical Medical, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 144.7% below estimates on average.

Over the past six months, Strata Critical Medical, Inc. insiders filed 43 SEC Form 4 transactions — 26 sales and 17 purchases. On net that is roughly 571K shares disposed (about $25.5M), a signal worth weighing alongside the fundamentals.

SRTA Financials

SRTA Latest News

SRTA Analyst Consensus

SRTA MoonshotScore

SRTA Industrials Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources